Analyzing R&D Budgets: Grifols, S.A. vs Travere Therapeutics, Inc.

R&D Spending: Grifols vs. Travere - A Decade of Innovation

__timestampGrifols, S.A.Travere Therapeutics, Inc.
Wednesday, January 1, 201418075300047795223
Thursday, January 1, 201522419300050426000
Friday, January 1, 201619761700070853000
Sunday, January 1, 201728832000078168000
Monday, January 1, 2018240661000123757000
Tuesday, January 1, 2019276018000140963000
Wednesday, January 1, 2020294216000131773000
Friday, January 1, 2021354881000210328000
Saturday, January 1, 2022361140000235780000
Sunday, January 1, 2023330551000244990000
Loading chart...

Infusing magic into the data realm

A Decade of Innovation: R&D Spending in Biopharma

In the competitive world of biopharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Grifols, S.A. and Travere Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.

Grifols, S.A., a global leader in plasma-derived medicines, has consistently increased its R&D budget, peaking in 2022 with a 100% increase from 2014. This steady growth underscores Grifols' dedication to advancing its product pipeline and maintaining its market leadership.

Conversely, Travere Therapeutics, Inc., a company focused on rare diseases, has shown a more volatile R&D spending pattern. Despite fluctuations, Travere's R&D expenses surged by over 400% from 2014 to 2023, reflecting its aggressive pursuit of breakthrough therapies.

These trends highlight the diverse approaches within the industry, where both stability and bold investment can drive innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025